Marijuana Rescheduling Update: What Changed in the Last Six Months and What Employers Should Know Heading Into 2027
DEA hearings, a GAO pause, and Judge Julius's October 22 ruling mark a pivotal moment — here's what it means for employers and workplace drug testing.
Quick Answer
As of October 22, 2026, marijuana remains a Schedule I controlled substance under federal law. DEA Administrative Law Judge Derek Julius issued a ruling today that advances — but does not finalize — the federal rescheduling process. Rescheduling marijuana to Schedule III would not legalize recreational cannabis, would not federally mandate that employers stop testing for THC, and would not override state laws or DOT regulations requiring drug testing for safety-sensitive roles. Employers should maintain current drug testing programs and consult employment counsel before making any policy changes based on rescheduling developments.
Six Months That Changed the Cannabis Rescheduling Conversation
Since April 2026, the federal marijuana rescheduling process has moved through a compressed and consequential series of regulatory milestones. The U.S. Drug Enforcement Administration (DEA), operating under authority from the U.S. Department of Justice, has been conducting formal administrative proceedings to evaluate whether marijuana should be moved from Schedule I — defined as having no accepted medical use and high abuse potential — to Schedule III, which would acknowledge accepted medical uses and a lower abuse potential than Schedule I or II substances.
The DEA's rescheduling process operates under the Controlled Substances Act. A proposed rule was published following a Department of Health and Human Services recommendation. Administrative law hearings — the procedural mechanism for formal rulemaking — began in the summer of 2026 and have drawn significant participation from medical, research, public health, and industry stakeholders.
Throughout this period, employer obligations around workplace drug testing have remained unchanged. Employers who maintain THC-inclusive programs can continue using SAFElife urine drug test cups for pre-employment, random, and post-accident screening. Employers whose written policies exclude cannabis for certain positions can find compliant drug test kits without THC — available in multiple panel configurations for general workforce programs.
What Judge Julius's October 22 Ruling Actually Means
DEA Administrative Law Judge Derek Julius presided over the formal evidentiary hearings on marijuana rescheduling. An ALJ ruling in this context is a recommended decision within the administrative process — it does not independently change federal law. The DEA Administrator still must review the ALJ's recommended decision, consider the record, and issue a final rule. That final rule is then subject to the standard federal regulatory review process.
In practical terms: today's ruling advances the rescheduling process, but marijuana remains Schedule I as of October 22, 2026. The DEA's website at dea.gov remains the authoritative source for current scheduling status and any final rulemaking notices.
⚠ What Has Not Changed: Marijuana's current Schedule I status under the Controlled Substances Act. Federal contractor and DOT drug testing requirements. State drug testing laws that permit or require THC testing for safety-sensitive positions. Employer authority to maintain zero-tolerance drug testing policies that include THC.
Rescheduling vs. Legalization: A Critical Distinction for Employers
Rescheduling marijuana to Schedule III would be a significant federal policy shift — but it would not be legalization. Understanding that distinction is critical for employers building or reviewing drug testing programs heading into 2027.
Schedule III status means: the substance is recognized as having accepted medical uses, has moderate to low physical dependence potential, and remains a controlled substance. Prescription regulation, manufacturing controls, and federal oversight would continue under a different framework. Recreational use would remain federally illegal.
Schedule III status does not mean: employers must stop testing for THC. It does not create a federal employment protection for marijuana users. It does not override DOT regulations, federal contractor requirements, or state drug testing laws that permit or require THC testing for safety-sensitive roles.
✓ Employer Bottom Line: Even if marijuana is rescheduled to Schedule III, private employers in most states will retain the authority to test for THC and take adverse action based on positive results — particularly for safety-sensitive positions. Federal contractors and DOT-regulated employers will continue to operate under federal drug testing mandates regardless of scheduling status.
What This Means for Workplace Drug Testing in 2026 and 2027
The rescheduling conversation has created real confusion among employers — particularly those in states with medical or recreational marijuana laws who are trying to understand their obligations heading into 2027. Here is a clear framework for thinking through the implications:
DOT-Regulated Employers
Employers subject to DOT drug and alcohol testing requirements — trucking, rail, aviation, pipeline, transit — must continue testing for THC under federal regulations. DOT has been explicit that marijuana rescheduling does not change DOT testing requirements. THC remains a tested substance under all DOT agency drug testing programs.
Federal Contractors
Employers with federal contracts subject to the Drug-Free Workplace Act must maintain drug-free workplace programs. Federal law governs, and rescheduling marijuana to Schedule III does not remove it from the list of substances covered by federal drug-free workplace obligations.
Private Employers in Safety-Sensitive Industries
For construction, petrochemical, manufacturing, and other private employers in safety-sensitive industries, state law governs what drug testing is permitted or required. Most states that have legalized recreational marijuana still permit employers to maintain zero-tolerance THC policies for safety-sensitive roles. Employers should review their state's specific employment law provisions — not federal rescheduling status — to determine their testing authority.
Employers Considering THC-Free Panels
Some employers whose workforce is not in safety-sensitive roles and who operate in states with strong recreational marijuana employment protections have begun evaluating THC-free drug test panels for general workforce positions. This is a state-law and HR policy question — not a decision driven by federal rescheduling. For employers exploring this option, DrugScreens.com's drug test kits without THC collection offers 5-panel through expanded-panel options specifically designed to exclude the cannabinoid screen.
For a comprehensive employer guide to cannabis and drug testing as state and federal law continues to evolve, see our Cannabis and Workplace Drug Testing: The Employer's Guide to 2027.
What Employers Should Do Right Now
- Do not change your drug testing policy based on today's ALJ ruling. Marijuana remains Schedule I. No employer obligation has changed.
- Monitor the DEA's official rulemaking timeline at dea.gov. A final rule — not an ALJ recommendation — is the trigger for any regulatory change.
- Review your written drug testing policy with employment counsel to confirm it accurately reflects your state's current law and your industry's regulatory requirements.
- Confirm your panel configuration matches your policy. If your policy includes THC as a prohibited substance, your drug test cups and kits should include a THC assay. If your policy excludes THC for certain positions, use the appropriate THC-free panel.
- Prepare, don't react. If rescheduling is finalized, it will go through public comment and a final rule period. Employers will have time to assess the implications and consult counsel before making policy decisions.
Need Drug Test Kits That Match Your Policy?
DrugScreens.com carries THC-inclusive and THC-free urine drug test cups, dip cards, and saliva kits — available in bulk for employers across every industry. CLIA-waived, FDA-cleared, ready to ship.
Shop Drug Test SuppliesThis content is provided for general informational purposes only and does not constitute legal advice, regulatory guidance, or IRB or compliance consultation. DrugScreens.com supplies drug screening devices and does not provide laboratory services, medical diagnostics, IRB guidance, or drug testing program administration. Research teams should consult with their IRB, institutional compliance office, principal investigator, and qualified legal and regulatory counsel before implementing any drug screening protocol.
